Clinical trial Recruiting at 1 site Observational Ages 45 and up

Evaluating adverse drug reactions in patients taking multiple medications

Official title: The Texas Interprofessional Pharmacogenomics (IPGx) PILOT Cohort

Run by Texas A&M University · NCT06219720 · Data updated 2026-11-12

This study is testing how taking multiple medications affects side effects in at-risk patients to help doctors make better treatment choices.

Quick facts

Study typeObservational
Ages45 Years and up
SexAll
Enrollment50 (estimated)
SponsorTexas A&M University
Academic / other
Locations1 site (Bryan, Texas)
StatusRecruiting
StartedDecember 15, 2021
Main results expectedNovember 2026
Study endsNovember 2027
Registry record updatedSeptember 12, 2025
Trial IDNCT06219720 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are individuals aged 45 and over who are taking five or more medications, including over-the-counter drugs and supplements.

Probably not a fit

Patients with a history of certain cancers, active liver disease, or those who are in hospice care may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to assess the impact of polypharmacy on adverse drug reactions (ADRs) in at-risk patients using advanced pharmacogenomic technology. The study will analyze data from a pilot cohort to optimize pharmacotherapy regimens and develop a clinical decision support dashboard to identify necessary modifications in drug regimens. Additionally, it will evaluate the capacity of CYP P450 enzymatic pathways in patients on multiple medications and assess the feasibility of integrating informatics workflows between the laboratory and clinical practice.

Why it matters

Potential benefit: If successful, this study could lead to safer and more effective medication management for patients on multiple drugs, reducing the risk of adverse drug reactions.

How similar studies have gone: While there have been various medication management programs, this study's specific focus on pharmacogenomics in polypharmacy is relatively novel and has not been extensively tested.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* People taking 5 or more medications, including over the counter drugs, supplements, natural products, cannabis produces, or other recreational drugs
* Ability to give and comprehend the consent process.
* Consent to donate urine samples, genetic data through buccal swabs, undergo a comprehensive history and physical examination.
* All genders.
* Age 45 and over

Exclusion Criteria:

* Subject has been diagnosed or is being treated for any cancer other than basal cell cancer in the last 5 years. Patients with metastatic melanoma in the last 5 years will be excluded.
* Admitted to hospice.
* Patient has ever been diagnosed with Hepatitis B or C.
* Patient has ever been diagnosed with active liver disease, hepatomegaly, grossly abnormal liver function. Meld score \>10, ALT or AST \>100U/L or an AST/ALT ratio \>2
* Patients taking imidazole antifungal medication.
* Declines to participate or interact with staff/share their medical status.
* A diagnosis of Alzheimer's disease
* Pregnant patients will be excluded
* Unable/unwilling to consent.
* Unable to verbally communicate and comprehend English/Spanish language.

Where it's running

  • The Interprofessional Pharmacogenomics (IPGx) Clinic
    Bryan, Texas, United States
    Recruiting

Study contacts

  • Principal investigator: Kenneth S Ramos, MD — Texas A&M IBT
  • Study coordinator: Kenneth S Ramos, MD
  • Email: kramos@tamu.edu
  • Phone: 7136777740

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.